As a proud new member of the AstraZeneca family, #EsoBiotec continues to set new standards in pioneering biotechnological research. We are looking for inspiring leaders to drive innovation and development of our pioneering lentiviral therapies and bring more products to patients. Check out our most recent job openings with more to come. https://lnkd.in/esPS4rsD https://lnkd.in/eqZ3NRnj
About us
EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Mont-Saint-Guibert
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology
Locations
-
Primary
Get directions
Rue André Dumont 5
Mont-Saint-Guibert, 1435, BE
Employees at EsoBiotec
Updates
-
As a proud new member of the AstraZeneca family, #EsoBiotec continues to set new standards in pioneering biotechnological research. We are looking for inspiring leaders to drive innovation and development of our pioneering lentiviral therapies and bring more products to patients. Check out our most recent job openings with more to come. https://lnkd.in/esPS4rsD https://lnkd.in/eqZ3NRnj
-
As a proud new member of the AstraZeneca family, #EsoBiotec continues to set new standards in pioneering biotechnological research. We are looking for inspiring leaders to drive innovation and development of our pioneering lentiviral therapies and bring more products to patients. Check out our most recent job openings with more to come. https://lnkd.in/esPS4rsD https://lnkd.in/eqZ3NRnj
-
Acquisition of EsoBiotec is completed. See the press release. https://lnkd.in/e7ZwMbBu
-
We are proud to share that AstraZeneca is acquiring EsoBiotec! As an early-stage company pioneering in vivo cell therapies, we are advancing a platform with the potential to transform treatment delivery. Today, we announced a definitive agreement to join AstraZeneca. Our ENaBL platform is designed to eliminate traditional cell therapies' complex, time-consuming manufacturing process—replacing it with a simple IV injection that can be administered in minutes rather than weeks. CAR-T and other autologous therapies have revolutionized cancer treatment, but their high costs, logistical challenges, and long production timelines limit patient access. EsoBiotec’s in vivo approach has the potential to streamline treatment delivery, reduce barriers, and bring cell therapy to more patients faster. The acquisition deal includes an upfront payment of $425M, with up to $575M in milestone-based payouts. EsoBiotec will operate as a wholly owned subsidiary of AstraZeneca, further advancing in vivo cell therapy innovation. This marks a significant step toward making next-generation cell therapies more scalable and accessible. Read the full announcement here: https://lnkd.in/eNt6Wxtf #biotech #celltherapy #invivotherapy #astrazeneca #regenerativemedicine
-
-
Excited to announce that EsoBiotec has dosed the first patient in our ESO-T01 trial for multiple myeloma, achieving remarkable early results with no cancer cells detected in the bone marrow after just 28 days. This innovative therapy simplifies treatment by eliminating the need for lymphodepletion and delivering a single, quick intravenous dose. We're on the path to transforming CAR-T therapy and making it more accessible for patients everywhere.
-
Check out our latest Press Release: https://lnkd.in/eJF_Haik. We are thrilled to bring our ESO-T01 in vivo BCMA CAR to patients.